Humanigen’s (NASDAQ: HGEN) stock is up almost 13% premarket after the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) accepted its submission for marketing authorisation n for lenzilumab in COVID-19.
The submission has been accepted for an expedited COVID-related rolling review, with an assessment expected to occur more rapidly than a standard rolling review.
Leading up to the submission last month, Humanigen had several meetings with regulatory bodies in the UK, including a Rapid C-19 multiagency meeting with representatives from the MHRA, the Therapeutics TaskForce, the Department of Health and Social Care, National Health Service England and the National Institute for Health and Care Excellence.
“We are grateful this submission will receive expedited consideration by MHRA,” said Cameron Durrant, CEO of Humanigen.
“The global spread of variants of concern, such as the Delta variant, highlights the continued need for proven therapies that are variant-agnostic for millions who remain at risk of COVID-19,” he added.
Humanigen’s shares are up 13.21% premarket at $18.85, regaining some of its year to date losses.
Should You Invest in Humanigen Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now